PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.109202136157-59Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 DiabetesJang Won Sonhttp://e-enm.org/upload/pdf/enm-2021-109.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.109, http://e-enm.org/upload/pdf/enm-2021-109.pdf
Endocrinology and Metabolism10.3803/enm.2020.7812021361157-170Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse ModelJin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Limhttp://e-enm.org/upload/pdf/enm-2020-781.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2020.781, http://e-enm.org/upload/pdf/enm-2020-781.pdf
Diabetes10.2337/db13-07102013631101-110Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient MiceBilal A. Omar, Birgitte Andersen, Jacob Hald, Kirsten Raun, Erica Nishimura, Bo Ahrénhttps://journals.org/diabetes/diabetes/article-pdf/63/1/101/572758/101.pdf, https://journals.org/diabetes/diabetes/article-pdf/63/1/101/572758/101.pdf
Diabetes, Obesity and Metabolism10.1111/dom.1211920131619-21The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implicationsS. Madsbadhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12119, http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12119/fullpdf
Diabetes, Obesity and Metabolism10.1111/dom.146402022Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaalhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640
The British Journal of Diabetes & Vascular Disease10.1177/147465140810196120099244-52Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetesNigel Irwin, Marc Moodley, Peter R Flatthttp://journals.sagepub.com/doi/pdf/10.1177/1474651408101961, http://journals.sagepub.com/doi/pdf/10.1177/1474651408101961
Canadian Journal of Diabetes10.1016/s1499-2671(09)33334-12009333319Therapeutic potential of glucagon-like peptide-1 agonists in insulin-treated diabetes mellitusJ. Dupre, T.J. McDonaldhttps://api.elsevier.com/content/article/PII:S1499267109333341?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1499267109333341?httpAccept=text/plain
Diabetes, Obesity and Metabolism10.1111/j.1463-1326.2010.01313.x201013119-25Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetesJ. Z. Dong, Y. Shen, J. Zhang, N. Tsomaia, D. F. Mierke, J. E. Taylorhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1326.2010.01313.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2010.01313.x/fullpdf
Diabetic Medicine10.1111/j.1466-5468.2004.1180h.x200421s118-20Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetesJ. Rachmanhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1466-5468.2004.1180h.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1466-5468.2004.1180h.x/fullpdf
Atherosclerosis10.1016/j.atherosclerosis.2018.06.4492018275e151Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).M. Walus-miarka, B. Idzior-Walus, M. Kapusta, A. Trojak, P. Miarka, M.T. Maleckihttps://api.elsevier.com/content/article/PII:S0021915018307615?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915018307615?httpAccept=text/plain